[Effect of angiotensin II receptor antagonist on heart failure].

What Was Tested

The paper reports a study of Antihypertensive Agents, published as a randomized controlled trial.

The assessment of response to candesartan heart failure in Japan(ARCH-J) is a randomized, double-blind, placebo-controlled 6-month study enrolled 305 patients who has not been previously treated with ACE inhibitors, who had not been adequately controlled with ACE inhibitors or who were intolerant of ACE inhibitors.

Who Took Part

The study group was 305 patients.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Antihypertensive Agents group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Antihypertensive Agents.

The comparison arm used a placebo, so changes seen with Antihypertensive Agents could be set against what happens without it.

What Was Measured

The assessment of response to candesartan heart failure in Japan(ARCH-J) is a randomized, double-blind, placebo-controlled 6-month study enrolled 305 patients who has not been previously treated with ACE inhibitors, who had not been adequately controlled with ACE inhibitors or who were intolerant of ACE inhibitors.

PubMed files the paper under topics including Angiotensin Receptor Antagonists, Antihypertensive Agents, Benzimidazoles, Biphenyl Compounds, Clinical Trials as Topic, Heart Failure and Randomized Controlled Trials as Topic.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Antihypertensive Agents in 305 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2004 (Nihon rinsho. Japanese journal of clinical medicine), a journal based in Japan.

More context: all human trials.